GlassScriptPhysician profile
Arvinder S Chawla
NPI 1346253002
$6,687.88
in general payments reported to CMS, 2019-2025
36 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $966 · 2021: $1,534 · 2022: $745 · 2023: $990 · 2024: $837 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,748 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,748.38 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,644.82 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Novo Nordisk INC | $1,592.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $578.51 | 2019-2025 | Qulipta, Ubrelvy, Synthroid |
| Lilly USA, LLC | $411.91 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $301.49 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $291.38 | 2023-2025 | |
| Esperion Therapeutics, INC. | $207.85 | 2021-2023 | Nexletol |
| Amarin Pharma, INC. | $176.22 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $166.04 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.11 | 2022-2025 | |
| Astellas Pharma US INC | $112.94 | 2023-2024 | Veozah |
| Amneal Pharmaceuticals LLC | $101.15 | 2024-2025 | Unithroid |
| Novartis Pharmaceuticals Corporation | $98.21 | 2022-2025 | |
| Allergan, INC. | $94.01 | 2019-2020 | |
| Dexcom, INC. | $77.00 | 2023-2024 | Dexcom G6 Transmitter |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvinder Chawla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.